Viewpoint March 11, 2015 What will change the NOAC landscape? Inside Edge Consulting, Princeton anticoagulation, apixaban, Consultant group, dabigatran, edoxaban, Health outcomes, Healthcare, Healthcare consultants, NOAC, Payers, Pharmacy, protola, reversal agent, rivaroxaban
